The Corticobasal Syndrome Functional Rating Scale (CBD-FRS) is a specialized clinical assessment tool designed to measure functional impairment and disease severity in patients with corticobasal syndrome (CBS), a progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and movement abnormalities.
The Corticobasal Syndrome Functional Rating Scale (CBD-FRS) is a specialized clinical assessment tool designed to measure functional impairment and disease severity in patients with corticobasal syndrome (CBS), a progressive neurodegenerative disorder characterized by asymmetric cortical dysfunction and movement abnormalities.
Overview
Mermaid diagram (expand to render)
CBD-FRS is used to:
Track disease progression over time
Assess the severity of functional impairment
Evaluate treatment efficacy in clinical trials
Guide clinical management decisions
The scale is specifically tailored to capture the unique constellation of symptoms seen in CBS, including motor dysfunction, cognitive impairment, and behavioral changes.
Domains Assessed
Motor Function
Limb rigidity: Assessment of axial and appendicular stiffness
Bradykinesia: Slowed movement and reduced spontaneous activity
Dystonia: Involuntary muscle contractions and abnormal postures
Myoclonus: Sudden, involuntary muscle jerks
Apraxia: Loss of learned motor movements
Cognitive Function
Executive dysfunction: Impaired planning, reasoning, and problem-solving
Language impairment: Progressive aphasia and verbal fluency deficits
Visuospatial dysfunction: Spatial orientation and constructional difficulties
Memory: Working memory and episodic memory assessment
Behavioral Changes
Alien limb phenomena: Feeling of foreignness in affected limbs
Apathy: Reduced initiative and motivation
Depression: Mood changes and emotional lability
Disinhibition: Impulsive behaviors and poor judgment
Functional Activities
Activities of daily living (ADLs): Basic self-care tasks
The CBD-FRS typically uses a ordinal scale with scores ranging from 0 (normal function) to 4 or 5 (severe impairment), with higher scores indicating greater disability.
| Score | Description | |-------|-------------| | 0 | Normal function | | 1 | Mild impairment | | 2 | Moderate impairment | | 3 | Severe impairment | | 4 | Complete loss of function |
Individual item scores are summed to generate total scores, which can be used to:
Track disease progression
Compare patients across studies
Monitor treatment response
Validation and Psychometric Properties
Reliability
Inter-rater reliability: Demonstrates moderate to good agreement between different assessors
Test-retest reliability: Shows acceptable consistency over short intervals
Internal consistency: Items demonstrate coherent measurement of the underlying construct
Validity
Content validity: Items comprehensively cover the breadth of CBS symptoms
Construct validity: Correlates with other established measures of motor and cognitive function
Criterion validity: Predictive of functional outcomes and disease progression
Sensitivity to Change
Demonstrates responsiveness to disease progression over time
Can detect clinically meaningful changes in function
Useful for monitoring treatment effects in clinical trials
Clinical Trial Usage
CBD-FRS has been incorporated as a secondary endpoint in several clinical trials for CBS and related 4R-tauopathies, including:
[Tau](/proteins/tau) inhibitor trials: Used to assess functional outcomes
The scale is particularly valuable in trials targeting:
Progressive supranuclear palsy (PSP)
Corticobasal degeneration (CBD)
Other 4R-tauopathies
Relationship to Other Scales
CBD-FRS shares conceptual similarities with:
MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale): For motor assessment
MoCA (Montreal Cognitive Assessment): For cognitive screening
ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living): For functional assessment
However, CBD-FRS is specifically designed to capture the asymmetric and heterogeneous presentation of CBS, which distinguishes it from more general Parkinson's plus syndrome scales.
Administration
Time Required
Complete assessment: 20-30 minutes
Training required for standardized administration
Clinician Qualifications
Typically administered by neurologists, movement disorder specialists, or trained research coordinators
Requires understanding of CBS presentation and progression
Frequency
Baseline assessment at diagnosis
Every 6-12 months for disease monitoring
As needed for treatment decisions
Limitations
Asymmetric assessment: May not fully capture the lateralized nature of CBS
Floor/ceiling effects: Some items may show limited range in early or late disease stages
Inter-rater variability: Requires training to minimize scoring differences
Limited validation data: Fewer validation studies compared to more established scales
Future Directions
Emerging developments include:
Digital CBD-FRS: Integration with wearable sensors for objective measurement
Computerized assessment: Tablet-based administration for standardized scoring
Item response theory: Refinement of item weighting based on psychometric analysis
Machine learning: Predictive modeling of disease progression